

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

Miraculins Inc. (the "Company")
6 – 1250 Waverley Street
Winnipeg, Manitoba
R3T 6C6

2. **Date of Material Change:**

December 4, 2014

3. **News Release:**

The Company issued a press release regarding the material change on December 4, 2014, a copy of which is attached hereto.

4. **Summary of Material Change:**

On December 4, 2014, the Company announced that granted an aggregate of 1,500,000 stock options at an exercise price of \$0.10 per common share, to certain directors, officers, employees, consultants and management company employees of the Company. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan.

5. **Full Description Of Material Change:**

See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

7. **Omitted Information:**

Not Applicable.

8. **Executive Officer:**

Christopher Moreau, Chief Executive Officer
Tel: (204) 477-7599

DATED at Winnipeg, Manitoba this 15th day of December, 2014.

MIRACULINS INC.

Per: ^{*“Christopher Moreau”*}
Christopher Moreau, President and
CEO

SCHEDULE “A”

Miraculins Announces Grant of Options

WINNIPEG, Manitoba – December 4, 2014 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has granted an aggregate of 1,500,000 stock options at an exercise price of \$0.10 per common share, to certain directors, officers, employees, consultants and management company employees of the Company. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option.

For more information, please contact:

Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1596

info@miraculins.com
www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.